Peptide therapy TikTok claims: what the science actually supports

What did @everydaywithsarahd actually say?

The creator was responding to a follower who started "reda" (retatrutide) and wasn't seeing results. Her core argument: retatrutide alone may not be enough if you're over 40, because you might also have insulin resistance, mitochondrial dysfunction, inflammation, or poor sleep. She named several peptides, including BPC-157, TB-500, KPV, and something called "Mott C," as potential additions to the stack. She also flagged basics like hydration, protein, and movement as missing pieces.

To her credit, this is framed as a thinking exercise, not a prescription. She says "I just want to give you something to think about" and "there's so much to the puzzle." But the mechanistic claims embedded in that framing, specifically about how retatrutide works, deserve closer scrutiny.

Does the science back this up?

Partially. Retatrutide's triple agonist mechanism is real and well-documented, but the explanation of how it handles insulin is oversimplified in ways that could mislead. The claim that it "allows insulin to get into the cells" misrepresents the pharmacology.

Retatrutide is a GIP, GLP-1, and glucagon receptor tri-agonist currently in Phase 3 trials. Its GLP-1 activity does improve insulin secretion and sensitivity over time, but it does not function as an insulin sensitizer in the way the creator describes. It does not physically escort insulin into cells. Insulin resistance involves complex signaling cascades, including IRS-1/PI3K/Akt pathway dysfunction, that retatrutide addresses indirectly through weight loss and GIP-mediated effects, not by acting as a cellular gatekeeper. The glucagon receptor activity does increase energy expenditure and fat oxidation, so that part of her description is closer to accurate. Jastreboff et al. (2023, NEJM) showed retatrutide produced up to 24.2% body weight reduction in a Phase 2 trial, the most substantial published figure for any obesity drug to date.

What did they get wrong (or right)?

The biggest error is the mechanistic description of insulin. Saying retatrutide "allows insulin to get into the cell" is not how this works. Insulin itself is a signaling molecule that binds to receptors on cell surfaces. It does not enter cells in the way this description implies. Retatrutide improves insulin sensitivity as a downstream effect of weight reduction and its GIP agonism, not by acting as a chaperone for insulin molecules. This is a meaningful distinction because it shapes how people understand why results might be delayed or incomplete.

What she got right: the observation that retatrutide is not as potent a food noise suppressant as tirzepatide or semaglutide is plausible given its glucagon component, which is more thermogenic than anorectic. The general principle that weight loss resistance in people over 40 can involve multiple overlapping factors, sleep, inflammation, movement, protein intake, is well-supported. She does not overclaim the peptide stack cures anything, which keeps her within a defensible range, even if the stack itself carries regulatory and safety questions.

What should you actually know?

Retatrutide is not approved by the FDA as of mid-2025. It is available only through compounding pharmacies operating under specific regulatory frameworks, and its long-term safety profile is still being established through active clinical trials. Stacking it with peptides like BPC-157, TB-500, and KPV introduces compounding variables that have not been studied in combination in human trials. BPC-157 has compelling animal data (Chang et al., 2011, Journal of Physiology-Paris) but no completed Phase 2 or Phase 3 human trials. TB-500 (thymosin beta-4 fragment) is similarly under-studied in humans.

The "Mott C" reference is almost certainly MitoQ or a mitochondria-targeted supplement, though it's unclear from context. If it refers to a specific peptide, no peer-reviewed evidence base was cited because none was offered. Anyone considering a multi-peptide stack for weight loss should be working with a licensed provider who can assess interactions, monitor labs, and adjust based on individual response, not building a protocol from social media content.

• Retatrutide is investigational. Phase 3 data is not yet published as of this writing.
• Food noise reduction varies by individual and mechanism. GLP-1 agonism drives most appetite suppression in this class.
• Peptide stacks are not standardized and carry uncharacterized interaction risks.
• Protein intake, sleep, and movement are not optional add-ons. They are independent variables with substantial effect sizes on body composition.